رادار التجارب السريرية

Patients who underwent allogeneic hematopoietic stem cell transplantation (HSCT) between March 2019 and March 2024;

Donor had fasting blood glucose and/or HbA1c records

Eastern Cooperative Oncology Group (ECOG) physical fitness score of 0-2

Survived at least 12 weeks after HSCT

Voluntarily signed the Informed Consent Form

Had appropriate organ function;

Laboratory results within 7 days prior to HSCT met the following criteria:

1. Aspartate aminotransferase (AST) ≤ 3-fold (upper limit of norma, ULN);
2. Alanine aminotransferase (ALT) ≤ 3x ULN;
3. Total serum bilirubin ≤ 1.5 times the upper limit of normal ULN unless the patient has documented Gilbert syndrome; patients with Gilbert-Meulengracht syndrome with bilirubin ≤ 3.0 times the upper limit of normal and direct bilirubin ≤ 1.5 times the upper limit of normal may be included;
4. Serum creatinine ≤ 1.5 times ULN or creatinine clearance ≥ 60 mL/min;
5. Coagulation function: International Normalized Ratio (INR) ≤1.5×ULN, Activated Partial Thromboplastin Time (APTT) ≤1.5×ULN;